|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
HIV |
|
ɱ���� |
|
Ԥ�� |
|
Ͷҩ,������ |
| ��������������� | |
|
������ |
|
������ |
| PubMed | |
|
Article by |
|
Article by |
������ɱ����Ԥ��HIV�������о���չ
������, ������
�й�ҽѧ��ѧԺ���й�Э��ҽ�ƴ�ѧƤ�����о��� �Ͼ� 210042
Ŀǰ,ͨ���ԽӴ�����HIV����������,�ر���ͨ�����ԽӴ���Ϊ��Ů��ȾHIV����Ҫ;�������˰�ȫ��ʹ����,��Ůʹ�õ�������ɱ�������һ����Ҫ���ֶΡ�Ŀǰ�ж����ٴ�ǰ���ٴ��о�����������ɱ���������о�,���ֶ��ֻ��Գɷֿ��Զ�HIV�ĸ�Ⱦ����������,������HIV�������������á��ı������ľֲ���������ǿ�ֲ������߷�Ӧ�������档
[2] Patton DL, Cosgrove Sweeney YT, Rabe LK, et al. Rectal applications of nonoxynol-9 cause tissue disruption in a monkey model. Sex Transm Dis, 2002, 29:581-547.
[3] Fichorova RN, Tucker LD, Anderson DJ. The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis, 2001, 184:418-428.
[4] Tevi-Benissan C, Makuva M, MorelliA,et al. Protection of cynomolgus macaque against cervicovaginal transmission of SIVmac251 by the spermicide benzalkonium chloride. J Acquir Immune Defic Syndr, 2000, 24:147-153.
[5] Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother, 2001, 45:664-672.
[6] Esser MT, Mori T, Mondor I,et al. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J Virol, 1999, 73:4360-4371.
[7] Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses, 2003, 19:535-541.
[8] Herold BC, Scordi-Bello I, Cheshenko N, et al. Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry.J Virol, 2002, 76:11236-11244.
[9] Neurath AR, Strick N, Li YY. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis, 2002, 2:27.
[10] Manson KH, Wyand MS, Miller C, et al. Effect of a cellulose acetate phthalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother, 2000, 44:3199-3202.
[11] Howett MK, Neely EB, Christensen ND, et al. A broad-spectrum microbicide with virucidal activity against sexually transmitted viruses. Antimicrob Agents Chemother, 1999, 43:314-321.
[12] D'Cruz OJ, Waurzyniak B, Yiv SH, et al. Evaluation of subchronic (13-week) and reproductive toxicity potential of intravaginal gel-microemulsion formulation of a dual-function phenyl phosphate derivative of bromo-methoxy zidovudine (compound whi-07) in B(6)C(3)F(1) mice. J Appl Toxicol, 2000, 20:319-325.
[13] D'Cruz OJ, Waurzyniak B, Yiv SH, et al. Evaluation of subchronic (13 weeks) and reproductive toxicity potential of intravaginal gel-microemulsion formulation of a dual-function phenyl phosphate derivative of bromo-methoxy zidovudine (compound WHI-05) in B(6)C(3)F(1) mice. Contraception, 2000, 61:69-76.
[14] D'Cruz OJ, Uckun FM. Pre-clinical safety evaluation of novel nucleoside analogue-based dual-function microbicides (WHI-05 and WHI-07). J Antimicrob Chemother, 2002, 50:793-803.
[15] D'Cruz OJ, Waurzyniak B, Uckun FM. A 13-week subchronic intravaginal toxicity study of the novel broad-spectrum anti-HIV and spermicidal agent, N-[2-(1-cyclohexenyl)ethyl] -N'-[2-(5-bromopyridyl)] -thiourea (PHI-346) in mice. Toxicol Pathol, 2002, 30:687-695.
[16] Di Fabio S, Van Roey J, Giannini G,et al. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation. AIDS, 2003, 17:1597-1604.
[17] Borkow G, Salomon H, Wainberg MA, et al. Attenuated infectivity of HIV type 1 from epithelial cells pretreated with a tight-binding nonnucleoside reverse transcriptase inhibitor. AIDS Res Hum Retroviruses, 2002, 18:711-714.
[18] Low-Beer N, Gabe R, McCormack S, et al. Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr, 2002, 31:391-398.
[19] Van Damme L, Wright A, Depraetere K,et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Infect, 2000,76:126-130.
[20] Clarke JG, Peipert JF, Hillier SL, et al. Microflora changes with the use of a vaginal microbicide.Sex Transm Dis, 2002, 29:288-293.
[21] van De Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr, 2001, 26:21-27.
[22] Bentley ME, Morrow KM, Fullem A, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect, 2000, 32:184-188.
[23] Coetzee N, Blanchard K, Ellertson C, et al. Acceptability and feasibility of Micralax applicators and of methyl cellulose gel placebo for large-scale clinical trials of vaginal microbicides. AIDS, 2001, 15:1837-1842.